Cadrenal Therapeutics (CVKD) vs Mustang Bio (MBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Cadrenal Therapeutics is the larger company by market cap ($3.2 million vs $3.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CVKD | MBIO |
|---|---|---|
| Share price | $0.9101 | $0.4001 |
| Market cap | $3.25M | $3.03M |
| 1-day change | -2.10% | -2.44% |
| EPS (TTM) | $-4.81 | $-0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.50 | $1.69 |
| 52-week low | $0.85 | $0.3802 |
| Distance from 52-week high | -93.72% | -76.33% |
| Analyst consensus | none | — |
| Avg. price target upside | +1438.29% | — |
| Average volume | 465.46K | 28.87K |
| Shares outstanding | 3.57M | 6.73M |
| Employees | 5 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Cadrenal Therapeutics
CVKD stock →Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Mustang Bio
MBIO stock →Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
CVKD vs MBIO FAQ
Which is bigger, Cadrenal Therapeutics or Mustang Bio?
Cadrenal Therapeutics (CVKD) is larger, with a market capitalization of $3.25M compared with $3.03M for Mustang Bio (MBIO).
Are Cadrenal Therapeutics and Mustang Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.